These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 31619453)

  • 21. Meningococcal Vaccination in Men Who Have Sex with Men.
    Blackwell CW
    Public Health Nurs; 2017 Mar; 34(2):147-151. PubMed ID: 27921318
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Meningococcus infection: problem actuality].
    Tereshchuk TO; Chugriiev AM
    Lik Sprava; 2011; (3-4):41-4. PubMed ID: 22416362
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Meningococcal disease in catalonia 1 year after mass vaccination campaign with meningococcal group C polysaccharide vaccine.
    Cardeñosa N; Domínguez A; Martínez A; Alvarez J; Pañella H; Godoy P; Minguell S; Camps N; Vázquez JA;
    Infection; 2003 Dec; 31(6):392-7. PubMed ID: 14735381
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands.
    de Greeff SC; de Melker HE; Spanjaard L; Schouls LM; van Derende A
    Pediatr Infect Dis J; 2006 Jan; 25(1):79-80. PubMed ID: 16395110
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vaccine Impact on Long-term Trends in Invasive Bacterial Disease in New Zealand Children.
    Walls T; Cho V; Martin N; Williman J; Brunton C
    Pediatr Infect Dis J; 2018 Oct; 37(10):1041-1047. PubMed ID: 30222697
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modern trends in mortality from meningococcal disease in Australia.
    Simpkins D; Wood N; Jelfs J; McIntyre PB; Menzies R; Lawrence G; Booy R
    Pediatr Infect Dis J; 2009 Dec; 28(12):1119-20. PubMed ID: 19858774
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recommendations for Use of Meningococcal Conjugate Vaccines in HIV-Infected Persons - Advisory Committee on Immunization Practices, 2016.
    MacNeil JR; Rubin LG; Patton M; Ortega-Sanchez IR; Martin SW
    MMWR Morb Mortal Wkly Rep; 2016 Nov; 65(43):1189-1194. PubMed ID: 27811836
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protecting UK adolescents and adults against meningococcal serogroup B disease.
    Vyse A; Ellsbury G; Madhava H
    Expert Rev Vaccines; 2018 Mar; 17(3):229-237. PubMed ID: 29374982
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Invasive meningococcal disease epidemiology and control measures: a framework for evaluation.
    Caro JJ; Möller J; Getsios D; Coudeville L; El-Hadi W; Chevat C; Nguyen VH; Caro I
    BMC Public Health; 2007 Jun; 7():130. PubMed ID: 17603880
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The yin and yang of fever after meningococcal B vaccination.
    Ladhani SN; Riordan A
    Arch Dis Child; 2017 Oct; 102(10):881-882. PubMed ID: 28931534
    [No Abstract]   [Full Text] [Related]  

  • 31. Control of invasive meningococcal disease: is it achievable?
    Marshall H; Wang B; Wesselingh S; Snape M; Pollard AJ
    Int J Evid Based Healthc; 2016 Mar; 14(1):3-14. PubMed ID: 26126001
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Meningococcal carriage in periods of high and low invasive meningococcal disease incidence in the UK: comparison of UKMenCar1-4 cross-sectional survey results.
    MacLennan JM; Rodrigues CMC; Bratcher HB; Lekshmi A; Finn A; Oliver J; Wootton M; Ray S; Cameron C; Smith A; Heath PT; Bartolf A; Nolan T; Hughes S; Varghese A; Snape MD; Sewell R; Cunningham R; Stolton A; Kay C; Palmer K; Baxter D; Suggitt D; Zipitis CS; Pemberton N; Jolley KA; Bray JE; Harrison OB; Ladhani SN; Pollard AJ; Borrow R; Gray SJ; Trotter C; Maiden MCJ
    Lancet Infect Dis; 2021 May; 21(5):677-687. PubMed ID: 33482143
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Community outbreak of serogroup B invasive meningococcal disease in Beaujolais, France, February to June 2016: from alert to targeted vaccination.
    Thabuis A; Tararbit K; Taha MK; Dejour-Salamanca D; Ronin V; Parent du Chatelet I; Spaccaferri G
    Euro Surveill; 2018 Jul; 23(28):. PubMed ID: 30017022
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MenACWY-TT vaccine for active immunization against invasive meningococcal disease.
    Papaevangelou V; Spyridis N
    Expert Rev Vaccines; 2012 May; 11(5):523-37. PubMed ID: 22827239
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact on disease incidence of a routine universal and catch-up vaccination strategy against Neisseria meningitidis C in Tuscany, Italy.
    Bechini A; Levi M; Boccalini S; Tiscione E; Balocchini E; Canessa C; Azzari C; Bonanni P
    Vaccine; 2012 Oct; 30(45):6396-401. PubMed ID: 22921931
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Meningococcal Diseases: Post Men C Vaccination Era.
    Ramly B
    Ir Med J; 2019 Jan; 112(1):860. PubMed ID: 30719901
    [No Abstract]   [Full Text] [Related]  

  • 37. Meningococcal Disease: Vaccines-Who's at Risk and the Future.
    O'Malley PA
    Clin Nurse Spec; 2018; 32(1):15-18. PubMed ID: 29200035
    [No Abstract]   [Full Text] [Related]  

  • 38. Meningococcal infections and meningitis: what is new?
    Kumar RK
    Aust J Rural Health; 2000 Dec; 8(6):318-21. PubMed ID: 11894791
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Invasive meningococcal disease in Navarra in the era of a meningococcal C vaccine].
    Morales D; Moreno L; Herranz M; Bernaola E; Martínez-Baz I; Castilla J
    An Pediatr (Barc); 2017 Apr; 86(4):213-219. PubMed ID: 26795260
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Cohn AC; MacNeil JR; Clark TA; Ortega-Sanchez IR; Briere EZ; Meissner HC; Baker CJ; Messonnier NE;
    MMWR Recomm Rep; 2013 Mar; 62(RR-2):1-28. PubMed ID: 23515099
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.